Sign in
Taking peoplePhase 3

Continuous Antibiotic Infusion In Children

Key facts

Who runs it
Tampere University Hospital
Where
Finland1 site in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
150 people, planned
Started
21 Apr 2026
Expected to end
31 Dec 2031
Type of study
Interventional
Treatments tested
  • Benzylpenicillin
Record updated
8 May 2026

Who can take part

Age
Up to 16 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • iv-antibiotic treatment is necessary
  • clinically stable
  • no need to stay in hospital
  • pump or cassette can be changed at the hospital or at home
  • care givers are able to contact hospital if needed
  • clinical diagnose is not uncertain
  • no allergy for the used antibiotic
  • the continuous antibiotic infusion hasn't been started yet or it has been initiated no more than 24 hours prior to study enrolment

Who cannot take part

  • the pump cannot be carried with the child
  • the child must stay at the hospital for monitoring or other reason
  • unclear diagnose

This trial is currently available in Finland.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Continuous intravenous antibiotic infusion using elastomeric pumps is well established in adult care and has been shown to be effective, safe, and cost-efficient, particularly for beta-lactams and vancomycin. In pediatric outpatient parenteral antimicrobial therapy (p-OPAT), home intravenous treatment is feasible and safe, improves quality of life, and reduces hospital stays and healthcare-associated infections. Elastomeric pumps offer practical advantages, including portability, ease of use, fixed infusion rates, and reduced drug handling, although they are limited by fixed flow rates and drug stability.

Read full original descriptionShow less

This prospective study at Tampere University Hospital (Tays) will evaluate the safety and cost-effectiveness of 24-hour continuous antibiotic infusions in children between January 2026 and January 2029. Eligible pediatric patients requiring intravenous antimicrobial treatment and suitable for home care will be included. Indications include serious bacterial infections such as bacteremia, osteomyelitis, septic arthritis, neutropenic fever, cystic fibrosis-related infections, and foreign body infections. The study antibiotics are benzylpenicillin, cloxacillin, piperacillin/tazobactam, and vancomycin, administered via CE-approved infusion devices for home use.

Children will receive continuous infusion either initially in hospital or directly from the emergency department if appropriate, with treatment duration and dosing comparable to standard intermittent regimens. Outcomes include safety, feasibility, cost-effectiveness, and patient-reported quality of life measured using PedsQL™. The study aims to determine whether continuous infusion can optimize pediatric antimicrobial care and healthcare resource utilization. Results will be published in peer-reviewed international journals.

The group in the trial

  • Continuous antibiotic infusionTreatment being tested

    Treatment: Benzylpenicillin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
8 May 2026